Literature DB >> 23919474

Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Nashwa El-Gendy1, Anubhav Kaviratna, Cory Berkland, Prajnaparamita Dhar.   

Abstract

Lung surfactant is crucial for optimal pulmonary function throughout life. An absence or deficiency of surfactant can affect the surfactant pool leading to respiratory distress. Even if the coupling between surfactant dysfunction and the underlying disease is not always well understood, using exogenous surfactants as replacement is usually a standard therapeutic option in respiratory distress. Exogenous surfactants have been extensively studied in animal models and clinical trials. The present article provides an update on the evolution of surfactant therapy, types of surfactant treatment, and development of newer-generation surfactants. The differences in the performance between various surfactants are highlighted and advanced research that has been conducted so far in developing the optimal delivery of surfactant is discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23919474      PMCID: PMC3840129          DOI: 10.4155/tde.13.72

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  181 in total

1.  Aerosolized surfactant treatment of preterm lambs.

Authors:  J F Lewis; M Ikegami; A H Jobe; B Tabor
Journal:  J Appl Physiol (1985)       Date:  1991-02

2.  Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.

Authors:  J Gadzinowski; K Kowalska; D Vidyasagar
Journal:  J Perinatol       Date:  2008-12       Impact factor: 2.521

Review 3.  Liquid and surfactant delivery into pulmonary airways.

Authors:  David Halpern; Hideki Fujioka; Shuichi Takayama; James B Grotberg
Journal:  Respir Physiol Neurobiol       Date:  2008-05-23       Impact factor: 1.931

4.  Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit.

Authors:  K M Ellyett; R S Broadbent; E R Fawcett; A J Campbell
Journal:  Pediatr Res       Date:  1996-06       Impact factor: 3.756

5.  A synthetic segment of surfactant protein A: structure, in vitro surface activity, and in vivo efficacy.

Authors:  F J Walther; R David-Cu; C Leung; R Bruni; J Hernández-Juviel; L M Gordon; A J Waring
Journal:  Pediatr Res       Date:  1996-06       Impact factor: 3.756

Review 6.  Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.

Authors:  Jan Mazela; T Allen Merritt; Janusz Gadzinowski; Sunil Sinha
Journal:  Acta Paediatr       Date:  2006-09       Impact factor: 2.299

7.  Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.

Authors:  Roger G Spragg; James F Lewis; Hans-Dieter Walmrath; Jay Johannigman; Geoff Bellingan; Pierre-Francois Laterre; Michael C Witte; Guy A Richards; Gerd Rippin; Frank Rathgeb; Dietrich Häfner; Friedemann J H Taut; Werner Seeger
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

8.  A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  J D Horbar; L L Wright; R F Soll; E C Wright; A A Fanaroff; S B Korones; S Shankaran; W Oh; B D Fletcher; C R Bauer
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

9.  Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure.

Authors:  Marco Luchetti; Federica Ferrero; Carla Gallini; Alfonso Natale; Antonia Pigna; Luca Tortorolo; Giuseppe Marraro
Journal:  Pediatr Crit Care Med       Date:  2002-07       Impact factor: 3.624

10.  Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.

Authors:  H Verder; P Albertsen; F Ebbesen; G Greisen; B Robertson; A Bertelsen; L Agertoft; B Djernes; E Nathan; J Reinholdt
Journal:  Pediatrics       Date:  1999-02       Impact factor: 7.124

View more
  8 in total

Review 1.  Challenges Associated with Route of Administration in Neonatal Drug Delivery.

Authors:  Matthew W Linakis; Jessica K Roberts; Anita C Lala; Michael G Spigarelli; Natalie J Medlicott; David M Reith; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Recent progress on surfactant protein A: cellular function in lung and kidney disease development.

Authors:  Skylar D King; Shi-You Chen
Journal:  Am J Physiol Cell Physiol       Date:  2020-07-08       Impact factor: 4.249

3.  Relationship of Notch Signal, Surfactant Protein A, and Indomethacin in Cervix During Preterm Birth: Mast Cell and Jagged-2 May Be Key in Understanding Infection-mediated Preterm Birth.

Authors:  Sema Avci; Nilay Kuscu; Leyla Kilinc; Ismail Ustunel
Journal:  J Histochem Cytochem       Date:  2021-12-20       Impact factor: 2.479

4.  Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia.

Authors:  Brandon J H Banaschewski; Edwin J A Veldhuizen; Eleonora Keating; Henk P Haagsman; Yi Y Zuo; Cory M Yamashita; Ruud A W Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

5.  Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

6.  Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

Review 7.  How to decrease bronchopulmonary dysplasia in your neonatal intensive care unit today and "tomorrow".

Authors:  Leif D Nelin; Vineet Bhandari
Journal:  F1000Res       Date:  2017-04-21

8.  Non-invasive administration of poractant-α in neonatal respiratory distress syndrome via a supraglottic device in the clinical practice in a second level neonatal unit: comparison of LMA® vs iGel® devices.

Authors:  Stefano Parmigiani; Giulio Bevilacqua
Journal:  Acta Biomed       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.